Skip NavigationSkip to Content

Massively parallel reporter assays and variant scoring identified functional variants and target genes for melanoma loci and highlighted cell-type specificity

  1. Author:
    Long, Erping
    Yin, Jinhu
    Funderburk, Karen M
    Xu, Mai
    Feng, James
    Kane, Alexander
    Zhang, Tongwu
    Myers, Timothy
    Golden, Alyxandra
    Thakur, Rohit
    Kong, Hyunkyung
    Jessop, Lea
    Kim, Eun Young
    Jones, Kristine
    Chari,Raj
    Machiela, Mitchell J
    Yu, Kai
    Iles, Mark M
    Landi, Maria Teresa
    Law, Matthew H
    Chanock, Stephen J
    Brown, Kevin M
    Choi, Jiyeon
  2. Author Address

    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA., Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea., Genome Modification Core, Frederick National Lab for Cancer Research, National Cancer Institute, Frederick, MD, USA., Leeds Institute for Data Analytics, School of Medicine, University of Leeds, Leeds LS2 9NL, UK., Statistical Genetics, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia; Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia; School of Biomedical Sciences, University of Queensland, Brisbane, QLD, Australia., Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. Electronic address: jiyeon.choi2@nih.gov.,
    1. Year: 2022
    2. Date: Nov 18
    3. Epub Date: 2022 11 18
  1. Journal: American Journal of Human Genetics
  2. Type of Article: Article
  1. Abstract:

    The most recent genome-wide association study (GWAS) of cutaneous melanoma identified 54 risk-associated loci, but functional variants and their target genes for most have not been established. Here, we performed massively parallel reporter assays (MPRAs) by using malignant melanoma and normal melanocyte cells and further integrated multi-layer annotation to systematically prioritize functional variants and susceptibility genes from these GWAS loci. Of 1,992 risk-associated variants tested in MPRAs, we identified 285 from 42 loci (78% of the known loci) displaying significant allelic transcriptional activities in either cell type (FDR < 1%). We further characterized MPRA-significant variants by motif prediction, epigenomic annotation, and statistical/functional fine-mapping to create integrative variant scores, which prioritized one to six plausible candidate variants per locus for the 42 loci and nominated a single variant for 43% of these loci. Overlaying the MPRA-significant variants with genome-wide significant expression or methylation quantitative trait loci (eQTLs or meQTLs, respectively) from melanocytes or melanomas identified candidate susceptibility genes for 60% of variants (172 of 285 variants). CRISPRi of top-scoring variants validated their cis-regulatory effect on the eQTL target genes, MAFF (22q13.1) and GPRC5A (12p13.1). Finally, we identified 36 melanoma-specific and 45 melanocyte-specific MPRA-significant variants, a subset of which are linked to cell-type-specific target genes. Analyses of transcription factor availability in MPRA datasets and variant-transcription-factor interaction in eQTL datasets highlighted the roles of transcription factors in cell-type-specific variant functionality. In conclusion, MPRAs along with variant scoring effectively prioritized plausible candidates for most melanoma GWAS loci and highlighted cellular contexts where the susceptibility variants are functional. Published by Elsevier Inc.

    See More

External Sources

  1. DOI: 10.1016/j.ajhg.2022.11.006
  2. PMID: 36423637
  3. PII : S0002-9297(22)00497-9

Library Notes

  1. Fiscal Year: FY2022-2023
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel